Showing 7371-7380 of 7743 results for "".
- FDA Approves Novartis Drug Xolair for Chronic Idiopathic Urticariahttps://practicaldermatology.com/news/20140321-fda_approves_novartis_drug_xolair_for_chronic_idiopathic_urticaria/2459302/The FDA approved Xolair (Novartis, omalizumab) for the treatment of chronic idiopathic urticaria (CIU) for patients 12 years of age and older who remain symptomatic despite treatment with H1-antihistamine therapy. Xolair is not used to treat other forms of urticaria (
- Somersets Shaving and Skincare Now Available at Walgreenshttps://practicaldermatology.com/news/20140321-somersets_shaving_and_skincare_now_available_at_walgreens/2459305/Somersets, a top-selling line of shaving and skincare products from the UK, has entered a new retail partnership with Walgreens. In support of the new distribution, Somersets will highlight Walgreens in promotional materials as well as an aggressive social media campaign. Products available at the l
- SeroVital®–hgh AKA the "Fountain of Youth" Pillhttps://practicaldermatology.com/news/20140320-serovitalhgh_aka_the_fountain_of_youth_pill/2459306/SeroVital®–hgh is a growth hormone that the maker says can reduce wrinkles, tighten skin, decrease body fat and increase energy. Gina Daines, spokesperson for SanMedica International™ said, "Human growth hormone is no longer solely the province of male athletes. Research is revealing tha
- Quinnova Pharmaceuticals Announces the Launch of Ecoza Foamhttps://practicaldermatology.com/news/20140319-quinnova_pharmaceuticals_announces_the_launch_of_ecoza_foam/2459310/Quinnova Pharmaceuticals LLC, an affiliate of Exeltis, launched its recently FDA-approved Ecoza (econazole nitrate) topical foam 1%. Ecoza Foma is indicated for the treatment of inter
- Ferndale Healthcare Announces Partnership with Colon Cancer Alliancehttps://practicaldermatology.com/news/20140318-ferndale_healthcare_announces_partnership_with_colon_cancer_awareness/2459313/Ferndale Healthcare's RectiCare® Cream, intended to resolve all discomfort from rectal and anal conditions such as hemorrhoids and anal fissures, urges colon screening for cancer before individuals reach for their brand. The brand wants to promote individuals to not rush to treat when bleeding an
- Celebrity Who Has It? App and IMMUDYNE Have Combined for New Skincare Linehttps://practicaldermatology.com/news/20140314-celebrity_who_has_it_app_and_immudyne_have_combined_for_new_skincare_line/2459317/IMMUDYNE is partnering with Who Has It? App to promote the Company's skincare line, NAYAD Rejuvenating Serum and Moisturizer. NAYAD is a topical solution that naturally activates topical and circulatory immune system cells. "We believe that partnering with Jennifer Colli, her clie
- Deepak Chadha is New Vice President of Regulatory Affairs for Suneva Medicalhttps://practicaldermatology.com/news/20140311-deepak_chadha_is_new_vicepresident_of_regulatory_affairs_for_suneva_medical/2459319/Suneva Medical appointed Deepak Chadha to Vice President of Regulatory Affairs. Chadha's role will be leading the development and implantation of regulatory practices. Chairman and Chief Executive Officer, Nicholas L. Teti, Jr. said, “Deepak has been responsible for several global regula
- Aquavit Pharmaceuticals Appoints David J. Goldberg as Chief Medical Officerhttps://practicaldermatology.com/news/20140305-aquavit_pharmaceuticals_appoints_david_j_goldberg_as_chief_medical_officer/2459324/Aquavit Pharmaceuticals, Inc., appointed David J. Goldberg, MD, JD as its Chief Medical Officer. Dr. Goldberg is recognized nationally and internationally for his innovative work with skin lasers, cosmetic dermatology and facial rejuvenation techniques. Prior to joining Aquavit,
- Ellman to Launch PelleFirm at Annual Meeting of the AADhttps://practicaldermatology.com/news/20140227-ellman_to_launch_pellefirm_at_annual_meeting_of_the_aad/2459327/Ellman International, Inc., received FDA clearance to market its new PelleFirm RF Body Treatment System. The PelleFirm System is CE Marked for body skin tightening and cellulite reduction. In addition, it also has received FDA 510(K) clearance for tissue heating and the temporar
- Mirvaso Approved by the European Commissionhttps://practicaldermatology.com/news/20140226-mirvaso_approved_by_the_european_commission/2459330/The European Commission has granted marketing authorization in Europe for Galderma's Mirvaso (brimonidine) 3 mg/g gel. Mirvaso, an alpha-2 adrenergic receptor agonist that acts rapidly and can last for up to 12 hours, is indicated for the symptomatic tr